NCCN Guidelines: Acute Myeloid Leukemia, Version 3.2023, Focus on BPDCN
Posted: 05/22/2023 | By: Chase Doyle

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy characterized by the aggressive proliferation of precursors of plasmacytoid dendritic cells that frequently involves the bone marrow, skin, central nervous system, and other organs and tissues. In an article published by Pollyea et al in JNCCN–Journal of the National Comprehensive Cancer Network, the authors review the diagnosis and management of BPDCN as outlined in the NCCN Guidelines for acute myeloid leukemia (AML).

Question 1 of 5

What is the median overall survival of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) when treated with chemotherapy?

Choose 1